Bloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million


Ryan Allway

March 15th, 2022

News, Top News


SANTA BARBARA, Calif.March 15, 2022 /PRNewswire/ — Bloomios, Inc. (OTCQB: BLMS), a leading researcher, manufacturer and wholesaler of hemp-derived cannabinoid nutraceuticals and cosmetics, will begin trading on the OTCQB® Venture Market under the symbol, BLMS, at the opening of the market today.

 

(PRNewsfoto/Bloomios, Inc.)
(PRNewsfoto/Bloomios, Inc.)

Over the course of the past year, Bloomios has rapidly emerged as a premier manufacturer of private- and white-label hemp-derived cannabinoid products. This includes nutraceuticals and cosmetics that incorporate cannabidiol (CBD), the most popular cannabinoid of the more than 100 distinct cannabinoids that can be derived from hemp.

 

Bloomios also produces products featuring such alternative cannabinoids and peripheral components of hemp which share similar health benefits with CBD, like cannabigerol (CBG) for pain management and cannabinol (CBN) for sleep, as well as terpenes (or flavonoids) that create a beneficial entourage effect for the user.

 

Since Bloomios’ official launch in the fourth quarter of 2020, gross revenues have climbed from virtually zero to total more than $8 million by September 30, 2021, with demand exceeding supply.

 

Following a facility expansion and equipment upgrade, Bloomios has increased its production capacity by an estimated 300%. Bloomios products are now being distributed by hundreds of corporate customers across the U.S.

 

“As a fully-reporting, emerging growth company, our listing on the OTCQB greatly elevates our profile in the market, provides greater liquidity and helps broaden our shareholder base,” stated Bloomios CEO, Michael Hill. “The listing represents a major step in our long-term capital market strategy designed to build shareholder value and leverage our unique B2B value proposition in the fast-growing hemp-derived products space.”

 

Bloomios is targeting a North American CBD market that is projected to grow at a 33.3% compounded annual growth rate (CAGR) to reach $61.3 billion by 2027, with the market for alternative cannabinoids expected to grow at 20.1% CAGR to hit $26.2 billion by 2028.

 

The company is also looking to further expand into the high-margin nutraceuticals space that is also seeing tremendous growth, and it is currently evaluating several accretive M&A targets.

 

For more information about the company, go to bloomios.com or contact Ron Both or Justin Lumley at (949) 432-7557 or [email protected].

 

About Bloomios
Bloomios, Inc. researches, manufactures, markets and distributes U.S. hemp-derived cannabinoid supplements and cosmetic products through wholesale distribution channels and its wholly owned subsidiary, Bloomios Private Label. The company provides custom formulation, brand development, manufacturing and order fulfillment to a wide variety of customers, including small and major brands, chain stores, vape shops and distributors. It offers private- and white-label customers a collection of more than 200 customizable hemp products across 12 categories.

 

Bloomios is headquartered in Santa Barbara, California, with manufacturing and distribution in Daytona Beach, Florida.

 

To learn more, visitbloomios.com.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the sales of the company’s identity protection software products into various channels and market sectors, the issuance of the Company’s pending patent applications, COVID-19, and the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the company.

 

Investor Relations Contact:
Ronald Both or Justin Lumley
CMA Investor Relations
Tel (949) 432-7566
Email contact

 

Media Contact:
Tim Randall
CMA Media Relations
Tel (949) 432-7572
Email Contact

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading